GI Insights

Colonoscopies are an essential procedure, however the effectiveness in detecting colorectal cancer depends heavily on the quality of a patient’s bowel preparation. Here to discuss why some patients choose to skip this preventive procedure and what you can do to help reduce the chances of poor bowel preparation with Dr. Sophie Balzora is Dr. Carol Burke, Vice Chair of the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic.

CLEN/1109/2019/USa

Joining Dr. Sophie Balzora to discuss the different bowel preparation quality assessment scales available and the advantages of each is Dr. Jonathan Cohen, Clinical Professor of Medicine at NYU School of Medicine.

CLEN/1109/2019/USb

Dr. Lawrence Hookey joins Dr. Sophie Balzora to discuss the clinical trial of a next generation low volume prep with proven efficacy and an established safety profile and tolerability data.

An inadequate bowel preparation process experience should never be the factor that keeps patients from undergoing a colonoscopy, yet that’s the case for about one in four colonoscopies. That’s why gastroenterology expert Dr. Colleen Schmitt is here to share her thoughts on CLENPIQ (sodium picosulfate, magnesium oxide and anhydrous citric acid) Oral Solution as well as three factors that may help improve the patient journey.

Not every IBD patient fits into IBD care guidelines, which is why Dr. Gary Lichtenstein and Dr. Marla Dubinsky discuss the best ways to use these guidelines in your practice at the second annual Crohn’s and Colitis Congress in Las Vegas.

Not every IBD patient fits into IBD care guidelines, which is why Dr. Gary Lichtenstein and Dr. Marla Dubinsky discuss the best ways to use these guidelines in your practice at the second annual Crohn’s & Colitis Congress in Las Vegas.

Whether they’re not getting enough calories or not eating a balanced diet due to disease restrictions, patients with IBD often have difficulty maintaining a healthy diet. So how can you help them navigate these diet and nutrition challenges?

Filmed live at the 2018 Crohn's and Colitis Evening of Hope, Dr. James Lewis from the University of Pennsylvania discusses strategies you can implement in your practice.

Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography.

Vipul Jairath, MD, PhD, Ingrid Ordas, MD, PhD, Guangyong Zou, PhD, Julian Panes, MD, Jaap Stoker, MD, PhD, Stuart A Taylor, MD, Cynthia Santillan, MD, Karin Horsthuis, MD, Mark A Samaan, MD, Lisa M Shackelton, PhD, Larry W Stitt, MSc, Pieter Hindryckx, MD, PhD, Reena Khanna, MD, William J Sandborn, MD ,Geert D'Haens, MD, PhD, Brian G Feagan, MD, Barrett G Levesque, MD, and Jordi Rimola, MD, PhD

Magnetic resonance enterography is increasingly utilized for assessment of luminal Crohn's disease activity. The Magnetic Resonance Index of Activity and the London Index are the most commonly used outcome measures in clinical trials. We assessed the reliability of these indices and several additional items.

A consensus process clarified scoring conventions and identified additional items based on face validity. Four experienced radiologists evaluated 50 images in triplicate, in random order, at least 1 month apart, using a central image management system. Intra- and interrater reliability were assessed by calculating and comparing intraclass correlation coefficients.

Intrarater intraclass correlation coefficients (95% confidence intervals) for the Magnetic Resonance Index of Activity, London, and London "extended" indices and a visual analogue ...

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

Saartje Van de Vondel, MD, Filip Baert, MD, PhD, Christine Reenaers, MD, PhD, Stijn Vanden Branden, MD, Leila Amininejad, MD, Pieter Dewint, MD, PhD, Wouter Van Moerkercke, MD, Jean-François Rahier, MD, PhD, Pieter Hindryckx, MD, PhD, Peter Bossuyt, MD, Marc Ferrante, MD, PhD, and Belgian IBD Research and Development (BIRD)

Adalimumab (ADM) has been shown efficacious in ulcerative colitis (UC). In randomized controlled trials, dose escalation from 40 mg ADM every other week to 40 mg every week was required in 20%–25% of patients within 1 year. Real-life data suggest higher escalation rates. Attempts for dose de-escalation have not been studied yet. We assessed the need for, outcome of, and predictors of dose escalation and de-escalation in a large retrospective cohort of UC patients treated with ADM.

We included 231 consecutive patients from 10 Belgian centers initiating ADM treatment for active UC before September 1, 2015 (follow-up ≥1 year in each patient). We performed detailed chart review to identify variables associated with short-term clinical benefit (based on physician global assessment and absence of rectal bleeding at week 10), success ...

As the most common extraintestinal complication from IBD, iron deficiency anemia (IDA) can take a heavy toll on your patients’ quality of life. This activity will review those impacts, in addition to discussing the different therapies and resources that are available to both you and your IBD patients.